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Abstract Endothelin-converting enzyme-1 (ECE-1) is one of
the most important enzymes to convert big endothelin-1 (big ET-
1) to ET-1. To identify the inhibitors of ECE-1, we examined the
effects of variously substituted analogues of big ET-1 on ECE-1
activity using solubilized membranes prepared from human ECE-
1-expressed CHO-K1 cells. Among the big ET-1 analogues
tested, [Phe21]big ET-1(18^34) and [Ala31]big ET-1(18^34)
exhibited a significant inhibition of ECE-1. A kinetic analysis
revealed [Phe21]big ET-1(18^34) to be a competitive inhibitor
(Ki = 20.6 WM) and [Ala31]big ET-1(18^34) to be a non-
competitive inhibitor (Ki = 35.6 WM). These results not only
support the concept that ECE-1 recognizes big ET-1 both at the
P1 position and at the C-terminal region but also revealed that
these two regions are recognized by this enzyme in a different
manner.
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1. Introduction
Endothelin-1 (ET-1) is a potent vasoactive peptide consist-
ing of 21 amino acid residues with two disul¢de bridges [1].
For the biosynthesis of ET-1, an inactive intermediate form,
big ET-1, with 38 amino acid residues in humans is initially
produced from pro-ET-1, thereafter big ET-1 is converted
into an active form, ET-1, through a proteolytic cleavage
between Trp21 and Val22 by endothelin-converting enzyme-1
(ECE-1). ECE-1 protein was recently puri¢ed and its major
property as a neutral metalloprotease was clari¢ed [2,3]. The
primary structure of ECE-1 and the presence of two isoforms,
ECE-1K and ECE-1L, have also been revealed by the cloning
of ECE-1 cDNAs [4^10]. The isoforms of ECE-1 were shown
to be derived from one gene by alternative splicing based on
the genomic structure of the ECE-1 gene [11]. It has recently
been shown that ET-1 is essential for the normal development
of neural crest-derived tissue in the fetus [12] while it is also
involved in a number of disease models of adult animals and
in certain pathological conditions in humans [13]. The design
of speci¢c inhibitors of ECE-1 may thus lead to the develop-
ment of new treatments of these diseases, furthermore, these
inhibitors may contribute to the clari¢cation of the substrate
recognition mechanism of ECE-1.
In the present study, we demonstrated two big ET-1 ana-
logues which show di¡erent types of inhibition against ECE-1.
2. Materials and methods
2.1. Materials
Synthetic human ET-1(1^21) and big ET-1(1^38) were purchased
from Peptide Institute (Osaka, Japan). Variously substituted big ET
analogues [3], which were synthesized by the solid-phase method, were
supplied by Ciba-Geigy International Research Laboratories (Taka-
razuka, Japan). Porcine ECE was puri¢ed from porcine aortic endo-
thelia as previously described [3].
2.2. Cloning and transfection of human ECE-1 cDNA
A cDNA library was prepared in QZAP (Stratagene, CA, USA)
using poly(A) RNA from human umbilical vein endothelial cells
(HUVEC). 1.6 kbp of partial cDNA encoding an ECE-1 protein
was then obtained from normal human adrenal total RNA by reverse
transcription coupled to polymerase chain reaction (RT-PCR) using
oligonucleotides with sequences of 5P-AGAACTCCAACAGCAA-
CGTGATCC-3P and 5P-CCTTACCAGACTTCGCACTTGTGAG-3P
as sense and antisense primers, respectively, which were set based on
the bovine ECE-1 cDNA structure [6]. This cDNA was used as a
probe for screening a HUVEC cDNA library, and two types of
cDNAs, pHECE1A and pHECE1B, corresponding to human ECE-
1K and ECE-1L [4,9,11], respectively, were cloned. Nucleotide sequen-
ces were determined using a DSQ 1000 DNA autosequencer (Shimad-
zu Co., Kyoto, Japan). The cDNA insert of pHECE1A consisted of
2662 bp (311 to +2651; the numbers represent the nucleotide posi-
tions by designating the translation start site as +1) and that of pHE-
CE1B consisted of 2793 bp (3143 to +2650). A cDNA portion encod-
ing an entire ECE-1 protein of each ECE-1 clone (1K, 311 to +2359;
1L, 368 to +2374) was subcloned into the SRK promoter-based mam-
malian expression vector pME18S [14]. The resultant expression plas-
mid constructs (4 Wg), pME18SHECE1A and pME18SHECE1B, were
then transfected into CHO-K1 cells cultured in 100 mm dishes using
10 Wl of liposomes (Lipofectamine, Life Technologies, Grand Island,
NY, USA). The cells (4 dishes), harvested 48 h after transfection, were
homogenized with a Polytron homogenizer on setting 7 for 10 s twice
in 2 ml of 0.25 M sucrose containing a 25 mM HEPES bu¡er, pH 7.4,
1 mM phenylmethylsulfonyl £uoride, 5 Wg/ml of pepstatin A and 2 Wg/
ml of aprotinin (bu¡er A), and then centrifuged at 221 000Ug for
30 min. The resulting membrane fraction was solubilized in 0.4 ml
of bu¡er A containing 0.3% (w/v) Lubrol PX, and then was centri-
fuged again at 221 000Ug for 30 min. The resultant clear supernatant
was used for the assay of ECE-1 activity.
2.3. Assay of ECE-1 activity
The solubilized CHO-K1 membranes (3^5 Wg) were incubated for
6 h at 37‡C in 100 Wl of 0.2 M Tris-HCl, pH 7.0, containing varied
concentrations of big ET-1 and 0.5 mM p-chloromercuribenzoic acid
(pCMB) and 0.1 mM actinonin in the presence or absence of 5^100
WM big ET analogues. The reaction was terminated at every 1 h
incubation by the addition of 100 Wl of radioimmunoassay bu¡er
containing 2 mM EDTA and the amount of ET-1 that had been
formed was then measured by a speci¢c radioimmunoassay for the
carboxyl-terminal tail of ET-1 using As-N7 antiserum [15] as previ-
ously described [3]. As-N7 had no cross-reactivity with the big ET
analogues used in this study or their hydrolysis products. For the
assay of hydrolysis rates of big ET analogues, 10 WM of each big
ET analogue was incubated with the solubilized CHO-K1 membranes
in the presence of 0.5 mM pCMB and 0.1 mM actinonin for 30^120
min at 37‡C followed by the quanti¢cation of the peptide products by
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HPLC on an ODS-120T column (0.46U25 cm, Tosoh) as described
previously [3].
3. Results
3.1. Expression of human ECE-1K and ECE-1L in CHO-K1
cells
The CHO-K1 cells which were transfected transiently with
pME18S expression vector containing the cDNA insert of
pHECE1A showed the phosphoramidon-sensitive but thior-
phan-insensitive converting activity from big ET-1 to ET-1
to be characteristic of native ECE [2,3,15,16]. More than
95% of the expressed ECE-1 activity was localized in the
membrane fractions, and the Lubrol PX extracts from the
membrane fractions displayed ECE-1 activity of
0.192 þ 0.018 nmol of ET-1 formed/h/mg protein
(mean þ S.D., n = 4) using 0.2 WM big ET-1(1^38) as a sub-
strate, while the ECE-1 activity observed in the extracts pre-
pared from mock-transfected CHO-K1 cells was less than
0.0004 nmol/h/mg. CHO-K1 cells transfected with pME18-
SHECE1B showed essentially the same results as those with
pME18SHECE1A.
3.2. E¡ects of big ET analogues on ECE-1 activity
We previously showed that a linear peptide of big ET-
1(18^34) has the full substrate activity for the puri¢ed porcine
aortic ECE and various substitutions for the amino acid res-
idues of this linear peptide reduced its hydrolysis rate [3]. The
human ECE-1K expressed in CHO-K1 cells also e¡ectively
hydrolyzed the big ET-1(18^34). We then examined whether
or not these variously substituted analogues of big ET-
1(18^34) have any inhibitory activity against ECE-1. Among
the various big ET analogues examined, big ET-1(18^34) it-
self, [Phe21]big ET-1(18^34) and [Ala31]big ET-1(18^34) both
showed a signi¢cant inhibition of the ECE-1 activity ex-
pressed in the CHO-K1 membrane fractions (Table 1).
[Phe21]big ET-1(18^34) and [Ala31]big ET-1(18^34) suppressed
the conversion of big ET-1(1^38) to ET-1 dose-dependently,
and then decreased to 10^14% of the original rates at 100 WM
(Fig. 1). [D-Val22]big ET-1(16^38), which was reported to have
an inhibitory activity against ECE [17], did not show any
inhibition up to 100 WM, but reduced to 70% of the original
rates at 0.75 mM (Fig. 1). The hydrolysis rates of big ET
analogues themselves were 7.18 þ 0.58 and 2.01 þ 0.12 nmol/
h/mg protein (mean þ S.D., n = 3) for big ET-1(18^34) and
[Phe21]big ET-1(18^34), respectively, at 10 WM, but [Ala31]big
ET-1(18^34) was not hydrolyzed by the expressed ECE-1K. A
kinetic analysis of the hydrolysis rates of big ET-1(1^38) in
the presence of di¡erent concentrations of those big ET-1
analogues revealed [Phe21]big ET-1(18^34) to be a competitive
inhibitor (Ki = 20.6 þ 3.8 WM), and [Ala31]big ET-1(18^34) to
be a non-competitive inhibitor (Ki = 35.6 þ 8.1 WM) (Fig. 2).
Essentially similar kinetic results were thus obtained using
puri¢ed porcine aortic ECE (data not shown). The apparent
Michaelis constant (Km) for big ET-1(1^38) in the expressed
ECE-1K was 4.5 þ 1.2 WM (mean þ S.D., n = 3), which closely
agreed with the ¢ndings (Km = 3.3 þ 0.3 WM) obtained in the
puri¢ed porcine aortic ECE [3].
4. Discussion
Recent studies have suggested that ECE-1 recognizes a rel-
atively long C-terminal amino acid sequence in addition to the
processing site of big ET-1 as follows. Not only in vitro
[2,3,16,18^20] but also in vivo [21] investigations have shown
that phosphoramidon-sensitive ECE hydrolyzes big ET-1
more e⁄ciently than big ET-2 or big ET-3. This di¡erence
in the hydrolysis rate among big ET isopeptides has been
suggested to be mainly due to the di¡erence in their C-termi-
nal sequence, namely, it has been shown by measuring the
hydrolysis rates of variously substituted analogues of big
ET-1 that ECE recognizes predominantly the sequence from
His27 to Gly34 in the C-terminal of big ET-1 [3,19]. The im-
portance of Trp21 in the processing of big ET-1 has also been
demonstrated using puri¢ed ECE [3] and by site-directed mu-
tagenesis of prepro-ET-1 [22]. The mode of substrate recog-
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Table 1
E¡ects of various big ET analogues on the conversion rate of hu-
man big ET-1(1^38) by solubilized membranes prepared from hu-
man ECE-1K cDNA-transfected CHO-K1 cells
Big ET analogue Hydrolysis rate of big
ET-1(1^38) (%)
Big ET-1(1^38) 100
+big ET-1(18^34) 25
+big ET-1(17^26) 104
+[A20]big ET-1(18^34) 92
+[A21]big ET-1(18^34) 95
+[F21]big ET-1(18^34) 10
+[A22]big ET-1(18^34) 105
+[F22]big ET-1(18^34) 108
+[Q27,T28,A29]big ET-1(18^34)a 109
+[F21]big ET-2(18^34) 98
+[D-W21,D-V22]big ET-1(18^34) 105
+[D-V22]big ET-1(16^38) 96
+[A31]big ET-1(18^34) 14
aBig ET-2(18^34). E¡ects of big ET analogues on the conversion rate
of big ET-1(1^38) (NH2-C1SCSSLMDKECVYFCHLDII20W21V22N-
TPEH27V28V29PY31GLGSPRS38-COOH) were estimated by incubat-
ing 0.2 WM big ET-1(1^38) with the solubilized membranes in the
presence of 100 WM of each big ET analogue followed by an assay
of ET-1 produced by a speci¢c radioimmunoassay. The conversion
rate is expressed as the percent of that in the absence of an analogue,
which was 0.21 þ 0.01 nmol/h/mg protein (mean þ S.D., n = 3).
Fig. 1. Concentration-dependent inhibition of the ECE-1 activity in
solubilized membranes prepared from ECE-1K cDNA-transfected
CHO-K1 cells. The solubilized membrane fractions were incubated
with 0.2 WM human big ET-1(1^38) in the presence of various con-
centrations of [Phe21]big ET-1(18^34) (b), [Ala31]big ET-1(18^34)
(R) and [D-Val22] big ET-1(16^38) (a). The amounts of ET-1 pro-
duced were assayed at every 1 h incubation as described in Section
2. Data are represented as the mean þ S.D. of four independent ex-
periments in values relative to the activity in the absence of the big
ET-1 analogues. *P6 0.05; **P6 0.001 vs. the activity in the ab-
sence of the big ET-1 analogues, Student’s t-test.
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nition by ECE-1K is quite unique, because neutral endopepti-
dase 24.11 (NEP), which is thought to belong to the same
family as that of ECE-1 [5,6,11], recognizes only the hydro-
phobic amino acid residues at the processing site. The unique
character of the substrate recognition by ECE-1 also strongly
suggests that the variously substituted analogues of the big
ET-1 can inhibit the ECE-1 activity, furthermore, an analysis
of the inhibitory e¡ects of these analogues would thus be able
to assess the processing mechanism of ECE-1. The membrane
fractions prepared from CHO-K1 cells transfected with an
expression vector containing ECE-1K or -1L cDNA exhibited
approximately 10 times as much ECE-1 activity as the crude
membrane fractions prepared from vascular endothelial cells
[3,15], and the membranes prepared from the mock-trans-
fected cells showed substantially no ECE-1 activity. Thus,
the membrane extracts of pME18SHECE1A/B-transfected
CHO-K1 cells seem to be an appropriate ECE-1 source for
a study of the processing mechanism of ECE-1. In the present
study, the two big ET-1 analogues, [Phe21]big ET-1(18^34)
and [Ala31]big ET-1(18^34), in which the amino acid residue
of big ET-1(18^34) was replaced either at the P1 position
(Phe21) or at the C-terminal region (Ala31), showed an inhib-
itory activity against ECE-1, although the a⁄nity of these
inhibitors to ECE-1 was 5^8 times less than that of big ET-
1(1^38). [Phe21]big ET-1(18^34) behaved as a competitive in-
hibitor, while [Ala31]big ET-1(18^34) acted as a non-compet-
itive inhibitor. The di¡erence in the inhibitory fashion be-
tween these two analogues may suggest that Phe21 at the P1
position interacts with the processing center of ECE-1 while
Ala31 in the C-terminal region interacts with a site indispen-
sable for the ECE-1 activity, but which is di¡erent from the
processing center. It seems that phosphoramidon also inter-
acts with the processing center, because it has been shown to
be a competitive inhibitor of ECE-1 [20]. Morita et al. [17]
reported the inhibitory activity of [D-Val22] big ET-1(16^38)
using the crude extract of bovine aortic endothelial cells, and
showed an 85% inhibition of ECE by the addition of 1 mM
[D-Val22] big ET-1(16^38) when assayed using big ET-1(1^38)
at 1 WM. However, the inhibitory activity of [D-Val22] big ET-
1(16^38) was far less potent than that of [Phe21]big ET-
1(18^34) or [Ala31]big ET-1(18^34) (Fig. 1). The [Ala31]big
ET-1(18^34) demonstrated in the present study may be a use-
ful inhibitor for the ECE-1 study, because this analogue was
not substantially hydrolyzed by ECE-1.
In conclusion, we demonstrated that a modi¢cation of ami-
no acid residues at the P1 position and the C-terminal region
of big ET-1 produced e¡ective inhibitors of ECE-1, while the
big ET-1 analogues synthesized in this way exhibited a di¡er-
ent manner of inhibition, suggesting that ECE-1 recognizes
big ET-1 at the two sites. More detailed analyses by further
modifying the big ET sequence in combination with site-di-
rected mutagenesis of ECE-1 would be expected to clarify the
processing mechanism of this unique enzyme.
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